On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA Administrative Law Judge (ALJ) hearing that could determine whether adult-use cannabis joins state-licensed medical cannabis on Schedule III of the Controlled Substances Act, begins proceedings.
Since President Trump issued an executive order to expedite cannabis rescheduling in December 2025, questions over the legal implications of this route have hung over the industry.
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling in.
UK medical cannabis clinic Releaf has launched a new 24/7 on-demand legal support service for its prescribed patients, helping navigate common issues with their medication with professional guidance.
Earlier this week, the first official guidance on medical cannabis for police officers in England and Wales was made public.
Over seven years after medical cannabis was legalised in the UK, the National Police Chiefs’ Council has approved the first official guidance for medical cannabis.
Next Thursday, 6 November 2025, Business of Cannabis: New York returns to The Wythe Hotel, Williamsburg, uniting more than 300 leaders from across the cannabis ecosystem for a day of strategic dialogue, networking, and market insight.
First published on Cannabis Health In a landmark decision, Spain’s Council of Ministers has approved a Royal Decree regulating the medical use of cannabis-based preparations in hospital settings, marking the country’s first comprehensive framework for cannabis-derived medicines.
By Matt Maurer and Siena Hilley Bland of Torkin Manes LLP To date, and as matters currently stand, Cannabis NB, a subsidiary of the New Brunswick Liquor Corporation, is the only legal retailer of recreational cannabis in New Brunswick.
